BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15875221)

  • 1. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.
    Aleksa K; Matsell D; Krausz K; Gelboin H; Ito S; Koren G
    Pediatr Nephrol; 2005 Jul; 20(7):872-85. PubMed ID: 15875221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal ontogeny of ifosfamide nephrotoxicity.
    Aleksa K; Halachmi N; Ito S; Koren G
    J Lab Clin Med; 2004 Dec; 144(6):285-93. PubMed ID: 15614250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
    Roy P; Yu LJ; Crespi CL; Waxman DJ
    Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
    Roy P; Tretyakov O; Wright J; Waxman DJ
    Drug Metab Dispos; 1999 Nov; 27(11):1309-18. PubMed ID: 10534317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tubule cell model for ifosfamide nephrotoxicity.
    Aleksa K; Halachmi N; Ito S; Koren G
    Can J Physiol Pharmacol; 2005 Jun; 83(6):499-508. PubMed ID: 16049550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantioselective metabolism of ifosfamide by the kidney.
    Aleksa K; Ito S; Koren G
    Chirality; 2006 Jun; 18(6):398-405. PubMed ID: 16575879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
    Huang Z; Roy P; Waxman DJ
    Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS.
    Aleksa K; Nava-Ocampo A; Koren G
    Chirality; 2009 Jul; 21(7):674-80. PubMed ID: 18825700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.
    Granvil CP; Madan A; Sharkawi M; Parkinson A; Wainer IW
    Drug Metab Dispos; 1999 Apr; 27(4):533-41. PubMed ID: 10101149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
    McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
    Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.
    Lu H; Wang JJ; Chan KK; Philip PA
    Xenobiotica; 2006 May; 36(5):367-85. PubMed ID: 16854777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
    Schmidt R; Baumann F; Knüpfer H; Brauckhoff M; Horn LC; Schönfelder M; Köhler U; Preiss R
    Br J Cancer; 2004 Feb; 90(4):911-6. PubMed ID: 14970873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.
    Woodland C; Ito S; Granvil CP; Wainer IW; Klein J; Koren G
    Life Sci; 2000 Nov; 68(1):109-17. PubMed ID: 11132240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
    Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T
    Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.
    Raccor BS; Claessens AJ; Dinh JC; Park JR; Hawkins DS; Thomas SS; Makar KW; McCune JS; Totah RA
    Drug Metab Dispos; 2012 Jan; 40(1):54-63. PubMed ID: 21976622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
    Gerber JG; Rhodes RJ; Gal J
    Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CYP2B6 in stereoselective human methadone metabolism.
    Totah RA; Sheffels P; Roberts T; Whittington D; Thummel K; Kharasch ED
    Anesthesiology; 2008 Mar; 108(3):363-74. PubMed ID: 18292673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory monoclonal antibody to human cytochrome P450 2B6.
    Yang TJ; Krausz KW; Shou M; Yang SK; Buters JT; Gonzalez FJ; Gelboin HV
    Biochem Pharmacol; 1998 May; 55(10):1633-40. PubMed ID: 9633999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
    Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
    Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.